Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrates that mouse eyelashes can effectively model human eyelash growth to analyze morphology, development, and the effects of growth-stimulatory agents like bimatoprost.

This review synthesizes current knowledge on eyelash hair follicles, highlighting gaps in understanding their biology and proposing future research directions; it reports no new experimental findings.

This study found that while bimatoprost was safe for 16 weeks, it was not effective for eyelash growth in patients with significant loss due to alopecia areata, though some with less loss experienced growth.

Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.

This review discusses the various causes and associations of eyelash trichomegaly, including congenital syndromes, acquired conditions, and drug effects, without reporting new clinical results.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

This study found that children and adolescents with allergic diseases have significantly longer eyelashes compared to nonallergic controls.

In this case report, eyelash transplantation with leg hair resulted in less frequent maintenance and no need for perming compared to using nape hair donor sources.

This study found that using the novel eyelid shampoo ESL improved eyelid hygiene, reduced dry eye symptoms in meibomian gland dysfunction patients, and increased eyelash length over 8 weeks.

This study found that combining follicular isolation with de-epithelialization in eyebrow and eyelash transplantation led to better outcomes and fewer complications than using follicular isolation alone.

This study reports a good correlation between the curvature of human eyelashes and the displacement of the neutral axis, influenced by the non-uniform thickness of the outer cuticle layer.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

This study found that the Brigham Eyelash Tool for Alopecia (BELA) is a reliable measure for assessing eyelash loss in alopecia areata patients, demonstrating high inter- and intrarater reliability.

This report describes a rare case of acquired eyelash trichomegaly in a 16-year-old female with systemic lupus erythematosus, accompanied by diffuse hair loss and "lupus hairs" on the scalp.

Malnutrition can cause unusual eyelash growth and hair loss.

This study observed that postburn hair transplants, using follicular unit micro grafting, can effectively restore facial hair and scalp regions, with eyebrow and mustache restoration yielding the highest patient satisfaction.

This study found that full-thickness eyelid excision typically does not affect the number of eyelashes postoperatively, suggesting an increase in the growth phase of remaining follicles.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

The technique effectively makes Asian eyelashes look fuller and more natural.

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

This study found that applying 0.005% latanoprost topically to eyelashes significantly increased their length and darkened their color in healthy volunteers over three months, without causing any side effects or changes in intraocular pressure compared to a placebo.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

This systematic review identified that surgical treatments show a positive response for eyebrow and eyelash leukotrichia, while topical tofacitinib appears promising but requires further research to confirm its efficacy.

Most men prefer keeping their eyebrows over scalp hair.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.